Siyu Feng, PhD
About Siyu Feng, PhD
Siyu Feng, PhD, is a Senior Scientist at BridgeBio Oncology Therapeutics in South San Francisco, California, with extensive experience in bioengineering and molecular assay development. She has a strong background in developing small molecule inhibitors and has worked in both academic and industrial settings.
Work at BridgeBio
Siyu Feng currently serves as a Senior Scientist at BridgeBio Oncology Therapeutics, a position she has held since 2024. Her tenure at BridgeBio began in 2021 when she worked as a Scientist for three years. In her current role, she focuses on oncology therapeutics, contributing to the development of innovative treatments. Her experience at BridgeBio is complemented by her previous roles in both academic and industrial settings, enhancing her expertise in drug development.
Education and Expertise
Siyu Feng earned her Doctor of Philosophy (Ph.D.) in Bioengineering and Biomedical Engineering from the University of California, San Francisco, where she studied from 2014 to 2019. She also completed a Bachelor's degree in Bioengineering and Biomedical Engineering at Beihang University from 2010 to 2014. Additionally, she participated in an international exchange program at Czech Technical University in Prague, focusing on Biomedical/Medical Engineering. Her educational background supports her specialization in fluorescence microscopy and extensive laboratory experience.
Background
Siyu Feng has a diverse professional background that includes significant roles in both academia and industry. Before her current position at BridgeBio, she worked as a Postdoctoral Research Fellow at Genentech from 2019 to 2021. She also gained experience as a Catalyst Intern in Product Development at the University of California, San Francisco, and held various internships, including a role in the Discovery Oncology & Bioinformatics Department at Genentech. Her experiences have contributed to her strong analytical and problem-solving skills.
Achievements
Siyu Feng has contributed to the 'PI3Ka:RAS Breaker' program, where she led the cell biology team. This program focuses on the interaction between PI3Ka and RAS, which are significant oncogenes in cancer research. Her work includes developing novel small molecule inhibitors and she possesses over 11 years of laboratory experience in high-throughput genetic screening and molecular assay development. Her involvement in the Merck Biopharma Innovation Cup as a finalist in 2019 further highlights her commitment to advancing biopharmaceutical innovation.